Virtu KCG Holdings LLC Lowers Stake in Celsion Corporation (CLSN)

Virtu KCG Holdings LLC decreased its stake in shares of Celsion Corporation (NASDAQ:CLSN) by 16.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,661 shares of the biotechnology company’s stock after selling 9,663 shares during the period. Virtu KCG Holdings LLC owned approximately 1.24% of Celsion Corporation worth $104,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC increased its position in shares of Celsion Corporation by 100.8% during the first quarter. Renaissance Technologies LLC now owns 1,375,147 shares of the biotechnology company’s stock worth $397,000 after acquiring an additional 690,349 shares in the last quarter. Institutional investors and hedge funds own 7.46% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Virtu KCG Holdings LLC Lowers Stake in Celsion Corporation (CLSN)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/03/virtu-kcg-holdings-llc-lowers-stake-in-celsion-corporation-clsn.html.

Several brokerages have recently issued reports on CLSN. Maxim Group reissued a “hold” rating on shares of Celsion Corporation in a research report on Tuesday, August 15th. Zacks Investment Research downgraded shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Celsion Corporation has a consensus rating of “Hold” and an average price target of $12.63.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Institutional Ownership by Quarter for Celsion Corporation (NASDAQ:CLSN)

What are top analysts saying about Celsion Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celsion Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit